Sep 15 2010 (Vol. 30, No. 16)
Parkinson Disease Research in Doldrums
Discontinuation of PD Trial Highlights Hazards Inherent in Developing Drugs for This Indication
A recent GlobalData report stated that
Parkinson disease (PD) drug development in general, focused as it is on the dopamine pathway, is “increasingly hampered by a lack of innovation.” Compounds in late-stage development aim at the symptomatic treatment of the disease, as do current medications. Any company developing treatments for PD will need to overcome prevailing product weaknesses including psychiatric side effects and obsessive compulsive behaviors as well as limited efficacy, the report pointed out.
http://www.genengnews.com/gen-articl...doldrums/3417/